Apotex's ruxolitinib, a generic version of Jakafi, an oral medication used to treat certain types of myelofibrosis and polycythemia vera, is currently in development [1].
As per the FDA's website, Apotex has submitted an Abbreviated New Drug Application (ANDA) for ruxolitinib, which is currently under review [2].
According to DrugPatentWatch.com, a website that provides information on pharmaceutical patents and market exclusivities, the last patent for Jakafi expires in the United States on December 27, 2027 [3].
Given these data points, it is likely that Apotex's ruxolitinib will become available in the USA shortly after the expiration of the last patent for Jakafi, which would be in January 2028. However, this timeline may be subject to change based on various factors, including the FDA's review process and potential regulatory hurdles.
Sources:
[1] https://www.apotex.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212813 Orig1s000sml.rtf
[3] https://www.drugpatentwatch.com/patent/US-7291549